- Open Access
The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil
- Geraldo da Rocha Castelar-Pinheiro1Email author,
- Ana Beatriz Vargas-Santos2,
- Cleandro Pires de Albuquerque3,
- Manoel Barros Bértolo4,
- Paulo Louzada Júnior5,
- Rina Dalva Neubarth Giorgi6,
- Sebastião Cezar Radominski7,
- Maria Fernanda B. Resende Guimarães8,
- Karina Rossi Bonfiglioli9,
- Maria de Fátima Lobato da Cunha Sauma10,
- Ivânio Alves Pereira11,
- Claiton Viegas Brenol12,
- Evandro Silva Freire Coutinho13 and
- Licia Maria Henrique da Mota3
© The Author(s) 2018
- Received: 5 March 2018
- Accepted: 15 June 2018
- Published: 28 June 2018
There are few data on the epidemiology, clinical manifestations and management of RA in Brazil, even with the recognition of the high direct, indirect and societal costs of this disease. Herein, we report the formation of the REAL - Rheumatoid Arthritis in Real Life, the first nationally representative multicenter prospective observational study in Brazil.
The REAL study was designed to include a total of 1300 evaluable patients from 13 tertiary care public health centers specialized in RA management and representative of 5 regions of Brazil. Each center was expected to enroll ~ 100 consecutively seen patients and follow them prospectively in a systematic protocol-driven fashion with scheduled visits at baseline, 6 and 12 months. Core clinical, laboratory and patient-reported outcomes measures were required to be collected at each visit.
A total of 1115 patients (89.4% female, mean age of 56.7 years and median disease duration of 12.7 years) were enrolled from 11 participating centers. Almost 80% of patients were of middle-low or low socioeconomic classes. The median educational time was 8 years, with 3.23% being below literacy level. The interval between symptoms and diagnosis varied from 1 to 457 months (median 12 months). Almost half of the patients were on glucocorticoids, 96.5% on DMARDs, with 35.7% on biologics. Median HAQ-DI was 0.875, ranging from 0 to 3. Median DAS28-ESR was 3.5, with 58.7% of patients presenting moderate or high disease activity.
The first large cohort of Brazilian patients with RA in a real-life setting shows several striking differences from previously published cohorts from other countries. The long delay for diagnosis and start of DMARDs may partly explain the high frequency of erosive disease. An elevated percentage of patients on moderate or high disease activity was seen, despite of the high frequency of corticosteroid and biologics utilization. Data from this cohort may enable public health managers of developing countries better allocate the limited resources available for the care of RA patients.
- Rheumatoid arthritis
- Brazilian cohort
- Observational study
Rheumatoid arthritis (RA) is a systemic, chronic and progressive disease, characterized by synovial inflammation of peripheral joints. Inadequate treatment often results in reduced health-related quality of life and excess mortality . The current concept of RA management relies on early diagnosis, immediate initiation of a disease-modifying antirheumatic drug (DMARD) and effective suppression of inflammation . Advances in diagnostic tools, the availability of new therapeutic options, mainly the biologic agents, and the adoption of a treat-to-target strategy have been of utmost importance for improving patient outcomes . Despite all this progress, in many areas of the world, the diagnosis of RA is delayed and patients remain undertreated, resulting in great negative humanistic and socioeconomic impact [4, 5].
Brazil is the largest country in Latin America, with a multiethnic population of around 200 million inhabitants . There are few data on the epidemiology and management of RA in Brazil, even with the recognition of the high direct, indirect and societal costs of this disease . A better understanding of the profile of RA patients seen in public health care centers in Brazil can underpin public health policy, enabling a rational allocation of resources and the setting of priorities in this sector.
The REAL – Rheumatoid Arthritis in Real Life – is a multicenter prospective observational cohort study, with twelve-month follow-up period. The aims of this study were to describe the demographic, clinical and therapeutic features of Brazilian patients with RA, and to evaluate adherence to treatment, safety of pharmacologic treatment, and impact on quality of life, physical function and work capacity of these patients. In this first report of REAL study, we describe the methodology and the baseline characteristics of this cohort.
Thirteen tertiary care public healthcare centers (Appendix 1) specialized in RA management were selected to represent the five geographic regions in Brazil. Eventually, 11 centers from 4 regions enrolled in the program. The recruitment period started on August 12th, 2015 and ended on April 15th, 2016. Patients were followed for ~ 12 months, with systematic data collection at the initial visit (baseline), at the intermediate visit (6 months ±1 month) and at the final visit (12 months ±1 month), with additional descriptive report of any other unscheduled visit.
The inclusion criteria were 1) fulfillment of the 1987 American Rheumatism Association (ARA) or the 2010 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis [8, 9]; 2) age 18 years or older; and 3) documented medical record data of at least 6 months of follow up in their healthcare center prior to study enrollment.
Each center was expected to enroll ~ 100 patients consecutively. Since all centers were tertiary-care academic rheumatology practices, they were requested to limit the enrollment of biologic-treated patients to roughly the proportion of these patients being treated in their center.
Variables, data sources and data collection
Variables assessed in study visits
(6 ± 1 months)
(12 ± 1 months)
Medical history with chart review
Evaluation of inclusion and exclusion criteria
Time from symptoms onset to diagnosis
Time from symptoms onset to the 1st DMARD
Local and medical specialty of the physician on the 1st appointment related with the onset of symptoms
Previous medications/ injections
History of joint surgeries
Physical exercise frequency
Medications in use/injections
Body mass index
Patient reported outcomes
Functional capacity (HAQ-DI)
General health (VAS)
Disease activity within in the previous 6 months VAS
Current disease activity VAS
Morning stiffness (VAS)
Quality of life (SF-12 / SF-6D)
DMARD use and adherence
Articular index assessment
Erythrocyte sedimentation rate (mm)
C-reactive protein (mg/dL)
Anti-citrullinated protein antibody
Bone erosions of hands and feet
Assessment of disease activity by a rheumatologist
Disease activity index
Brazilian Economic Classification Criterion (BECC): relation between socioeconomic strata and estimated household income
Household income (US dollara)
The study physician also assessed the following RA aspects: disease duration, time between symptoms onset and diagnosis, time to first DMARD prescription, health facility and physician specialty at first contact with healthcare due to RA symptoms, presence of extra-articular manifestations, positive rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA), and presence of bone erosions on radiographic study on both hands and feet. Erosive disease was defined when an erosion (defined as a cortical break) was seen in at least three separate joints at any of the following sites: the proximal interphalangeal, the metacarpophalangeal, the wrist (counted as one joint) and the metatarsophalangeal joints. In addition, prior pharmacologic treatments for RA were described (with respective reasons for discontinuation), history of orthopedic surgery and history of intra-articular or periarticular steroid injections.
Clinical evaluation included vital signs, anthropometric measures, tender and swollen joint counts, and physician score on the visual analogue scale (VAS) of disease activity. Patient reported outcomes included pain (VAS), global health (VAS), current and previous 6 months disease activity (VAS), fatigue (VAS), morning stiffness (VAS) and articular index, in which the patient evaluates the presence of pain and respective intensity in 16 joints. All laboratory tests, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were recorded. Compliance to prescribed medications as well as scheduled medical appointments and laboratory tests were also recorded.
The disease activity score-28 joints (DAS28), clinical disease activity index (CDAI), simplified disease activity index (SDAI) and the rheumatoid arthritis disease activity index (RADAI) were also calculated for each appointment [11–13].
The translated and validated versions of the Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form-12 (SF-12) and SF-6D evaluated, respectively, physical function, functional capacity and wellbeing, and health status from the patient’s perspective [14–16].
In this report, we summarize important demographic and clinical data at the baseline visit of all enrolled patients.
Intermediate and final visits
At the intermediate and the final visits, some variables from the medical history, such as change in the marital and employment status, onset of new extra-articular manifestations or comorbidities and medical intercurrences were reassessed. All the items within the physical exam domain, the patient reported outcomes, the lab tests ESR and CRP along with the disease activity indexes, were evaluated at the three scheduled visits (Table 1). Additionally, at the final visit, physicians were requested to describe their therapeutic plan.
This study was approved by the National Commission of Ethics in Research (CONEP - Comissão Nacional de Ética em Pesquisa) – Ministry of Health. The coordinating center was the Rio de Janeiro State University, and the approval number was 45781015.8.1001.5259. Each of the centers also obtained approval from the respective Institutional Review Boards. All patients signed the informed consent form.
Baseline demographic data of patients enrolled in the REAL study
Absolute value or %
Age, years, median (range)
Female gender, %
BMI categories, %
Total formal education time, years, median (range)
Brazilian Economic Classification Criterion: Socioeconomic Strata: Gross family income in the month in US dollarb, %
Baseline clinical data of patients enrolled in the REAL study
Absolute value or %
Disease duration, years, median (range)
Time from symptoms to diagnosis, months, median (range)
Time from symptoms to 1st DMARD, months, median (range)
Patients with ≥1 extra-articular manifestation, %
Positive rheumatoid factor, %
Positive anti-citrullinated peptide antibody, %
Erosive disease, %
Patients fulfilling classification criteria, %:
Drugs in use, %:
Nonsteroidal anti-inflammatory drugs
Biologic DMARD in monotherapy
ESR, median (range)
CRP median (range)
Pain (VAS 0–100), median (range)
Fatigue (VAS 0–100), median (range)
Global health assessment (VAS 0–100), median (range)
DAS28-ESR, median (range)
Low disease activity
Moderate disease activity
High disease activity
CDAI, median (range)
Low disease activity
Moderate disease activity
High disease activity
HAQ-DI, median (range)
SF-12 physical, median (range)
SF-12 mental, median (range)
The interval between symptoms and diagnosis varied from 1 to 457 months (median 12 months). The gap between symptoms onset and first DMARD initiation was wider, ranging from 1 to 624 months, but the same median value of 12 months.
The seropositivity rate was similar between RF (78%) and ACPA (77%), but it is important to highlight that the latter was assessed in less than half of the patients.
Interestingly, similar numbers of patients fulfilled the ARA 1987 and the 2010 ACR-EULAR classification criteria for RA, with 80.8% of subjects meeting both criteria. All patients met at least one criteria.
Almost half of the patients were on glucocorticoids, 96.5% on DMARDs, with 35.7% on biologics. Of those on biologics (n = 398), 15.6% were on monotherapy.
Median HAQ-DI was 0.875, ranging from 0 to 3. Median DAS28-ESR was 3.5, with 58.7% of patients presenting moderate or high disease activity. When assessed by CDAI, the median score represented low disease activity (CDAI = 9), with 46.7% of subjects classified as presenting moderate to high disease activity.
We describe the formation of the first large cohort of Brazilian patients with RA in a real-life setting, with consecutive enrollment of subjects and systematic data collection. The demographic, clinical, serological and radiographic characteristics of the patients being followed have several similar but some divergent characteristics from previously published North American, European and Latin American cohorts [17–21]. Particularly notable are the long delay for diagnosis, the high frequency of corticosteroid use and of erosive disease, as well as, the elevated percentage of patients on moderate or high disease activity. The high frequency of biologic DMARD use, considering the economic limitations in Brazil, is also remarkable. The fact that most patients were either RF or ACPA positive and had a delay in the initiation of DMARD may explain the observed high frequency (almost 60%) of moderate or high disease activity and erosive disease. The ethnic and socioeconomic class distribution reflects the Brazilian population in general, and is considerably different from other international cohorts [17–22]. It is important to note that the socioeconomic class distribution likely reflects the patients seen at the participating centers, which provide free health care within the Brazilian Public Health System -Sistema Único de Saúde (SUS). In Brazil, three quarters of the population is served by this public and free system, with the others using various private and paid health plans  and the latter were likely not represented to a significant degree in this study. About 11% of REAL patients were currently smokers, a number lower than that published in previous RA studies from other parts of the world (25–33%), but consistent with the relatively low rates of smoking in the Brazilian population (females: 8.2% and males: 12.6%) [24–27]. Subsequent publications will explore the relationship of these differences with clinical and outcome variables.
We recognize several limitations of the REAL study. All the sites enrolled in the study are “reference centers”, and thus are unlikely to represent the broader management of RA across the country. It is probable that these patients present more severe disease, with a less favorable prognosis. REAL study was designed to be representative of the entire Brazilian population, but one center in the Northeast (representing 27.9% of population) could not participate because of delays in the Ethics Committee approval. Also, our cohort does not include patients from among the 25% of Brazilian population receiving their healthcare outside of the public health system. On the other hand, the REAL study data reflects perhaps a more optimal standard of care possibly resulting in better outcomes in comparison with those treated in less prepared facilities. Further publications will study multiple management strategies and their effects on patient outcomes.
The first large cohort of Brazilian patients with RA in a real-life setting shows several striking differences from previously published cohorts from other countries. The long delay for diagnosis and start of DMARDs may partly explain the high frequency erosive disease. An elevated percentage of patients on moderate or high disease activity was seen, despite of the high frequency of corticosteroid and biologics utilization. Data from this cohort may enable public health managers of developing countries better allocate the limited resources available for the care of RA patients.
Gurkirpal Singh, MD and Leticia Rocha provided technical and writing assistance.
This work was supported by the Brazilian Society of Rheumatology (BSR). For this project, BSR received specific grant support from the following companies: Bristol-Myers Squibb Farmacêutica Ltda; Eli Lilly do Brasil Ltda; Janssen-Cilag Farmacêuticos Ltda; Laboratórios Pfizer Ltda; Produtos Roche Químicos e Farmacêuticos S.A. and UCB Biopharma Ltda. The funding body or the companies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
All authors made substantial contributions to the acquisition of data, have been involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of the version to be published and have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
In addition, GRCP, ABVS and LMHM also made substantial contributions to conception and design of the study.
Ethics approval and consent to participate
This study was approved by the National Commission of Ethics in Research (CONEP - Comissão Nacional de Ética em Pesquisa) – Ministry of Health. The coordinating center was the University of the State of Rio de Janeiro, and the approval number was 45781015.8.1001.5259. Each of the centers also obtained approval from the respective Institutional Review Boards. All patients signed the informed consent form.
GRCP: Has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche; ABVS: Has received supporting for international medical events from AbbVie and Janssen; CPA: Has received personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, outside the submitted work; MBB: Has participated in clinical and/or experimental studies related to this work and sponsored by Roche; has delivered speeches at events related to this work and sponsored by AbbVie and Pfizer; PLJ: Has received supporting for internationals congresses from Bristol-Myers Squibb, UCB and consulting fees from Pfizer; RDNG: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS; SCR: Has received consulting and speaking fees from Abbvie, Janssen, Pfizer, Roche and UCB; MFBRG: Has received speaking fees and supporting for congresses from AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Pfizer, Roche and UCB; KRB: Has received speaking fees and supporting for international congresses from Roche, Pfizer, Bristol-Myers Squibb, Abbvie and Janssen; MFLCS: No financial disclosures; CVB: Has participated in clinical and/or experimental studies related to this work and sponsored by AbbVie, BMS, Janssen, Pfizer and Roche; has received personal or institutional support from AbbVie, BMS, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer and Roche; IAP: Has received consulting fees, speaking fees and supporting for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, Abbvie and Janssen; ESFC: No financial disclosures; LMHM: Has received personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- van der Linden MP, Knevel R, Huizinga TW, et al. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European league against rheumatism criteria. Arthritis Rheum. 2011;63:37–42.View ArticlePubMedGoogle Scholar
- Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.PubMedGoogle Scholar
- Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.View ArticlePubMedGoogle Scholar
- Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database. Ann Rheum Dis. 2009;68:1666–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Burgos Vargas R, Cardiel MH. Rheumatoid arthritis in Latin America. Important challenges to be solved Clin Rheumatol. 2015;34(Suppl 1):S1–3.PubMedGoogle Scholar
- "World Population Prospects: The 2017 Revision” ESA.UN.org (custom data acquired via website). United Nations Department of Economic and Social Affairs, Population Division. https://www.un.org/development/desa/publications/world-population-prospects-the-2017-revision.html. Accessed 10 Feb 2018.
- Azevedo AB, Ferraz MB, Ciconelli RM. Indirect costs of rheumatoid arthritis in Brazil. Value Health. 2008;11:869–77.View ArticlePubMedGoogle Scholar
- Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.View ArticlePubMedGoogle Scholar
- Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.View ArticlePubMedGoogle Scholar
- ABEP. Brazilian Criteria 2015 and social class distribution update for 2016, ABEP - Associação Brasileira de Empresas de Pesquisa/Brazilian Market Research Association – 2016 – http://www.abep.org/criterio-brasil – Accessed 10 Feb 2018.
- van der Heidjde DMFM, van’t Hof MA, PLCM v R, de Putte LBA v. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20:579–81.Google Scholar
- Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(Suppl 39):S100–8.PubMedGoogle Scholar
- Stucki G, Liang MH, Stucki S, et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum. 1995;38:795–8.View ArticlePubMedGoogle Scholar
- Ferraz MB, Oliveira LM, Araujo PM, et al. Crosscultural reliability of the physical ability dimension of the health assessment questionnaire. J Rheumatol. 1990;17:813–7.PubMedGoogle Scholar
- Silveira MF, Almeida JC, Freire RS, et al. Psychometric properties of the quality of life assessment instrument: 12-item health survey (SF-12). Cien Saude Colect. 2013;18:1923–31.View ArticleGoogle Scholar
- Campolina AG, Bortoluzzo AB, Ferraz MB, et al. Validation of the Brazilian version of the generic six-dimensional short form quality of life questionnaire (SF-6D Brazil). Cien Saude Colet. 2011;16:3103–10.View ArticlePubMedGoogle Scholar
- Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40:2–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11:R7.PubMedPubMed CentralGoogle Scholar
- van der Zee-Neuen A, Putrik P, Ramiro S, et al. Large country differences in work outcomes in patients with RA – an analysis in the multinational study COMORA. Arthritis Res Ther. 2017;19:216.View ArticlePubMedPubMed CentralGoogle Scholar
- Estel BAP, Massardo L, Wojdyla D, et al. Is there something we can learn from rheumatoid arthritis in Latin America? A descriptive report on an inception cohort of 1093 patients [abstract]. Ann Rheum Dis. 2008;67:336.Google Scholar
- Cardiel MH, Pons-Estel BA, Sacnun MP, et al. Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol. 2012;18:327–35.View ArticlePubMedGoogle Scholar
- https://ww2.ibge.gov.br/english/estatistica/populacao/caracteristicas_raciais/default_raciais.shtm. Accessed 10 Feb 2018.
- Lewis M, Penteado E, Malik AM. Brazil’s mixed public and private hospital system. World Hosp Health Serv. 2015;51:22–6.PubMedGoogle Scholar
- Balsa A, Lojo-Oliveira L, Alperi-López M, et al. Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study. Reumatol Clin. 2017. https://doi.org/10.1016/j.reuma.2017.06.002. [Epub ahead of print]
- Meissner Y, Richter A, Manger B, et al. Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis. 2017;76:1583–90.View ArticlePubMedPubMed CentralGoogle Scholar
- GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389:1885–906.View ArticleGoogle Scholar
- Lotufo PA. Smoking control in Brazil: a public health success story. Sao Paulo Med J. 2017;135:203–4.View ArticlePubMedGoogle Scholar